Table 2.
Expression of PD-L1, PD-l, PRAME and MHC I in salivary duct carcinoma
| N | % | ||
|---|---|---|---|
| PD-L1 positivity (n=53) | CPS ≥1 | 35 | 66% |
| ≥1% TC | 17 | 32% | |
| ≥25% TC | 3 | 6% | |
| Percentage of PD-L1 positive tumor cells (n=53) | <1% | 36 | 68% |
| 1–4% | 9 | 17% | |
| 5–24% | 5 | 9% | |
| 25–49% | 1 | 2% | |
| ≥50% | 2 | 4% | |
| Percentage of PD-L1 positive immune cells (n=53) | <1% | 18 | 34% |
| 1–4% | 12 | 23% | |
| 5–24% | 15 | 28% | |
| 25–49% | 6 | 11% | |
| ≥50% | 2 | 4% | |
| PD-1 positive immune cells (n=53) | Negative (0/HPF) | 18 | 34% |
| Low (<25 PD1(+)-IC/HPF | 16 | 30% | |
| High (≥25 PD1(+)-IC/HPF | 19 | 36% | |
| PRAME in tumor cells (n=40) | Negative | 7 | 17.5% |
| Positive | 33 | 82.5% | |
| 1–24% TC | 10 | 25% | |
| 25–49% TC | 6 | 15% | |
| 50–74% TC | 9 | 23% | |
| 75–100% TC | 8 | 20% | |
| Pattern: cytoplasmic and nuclear | 7 | 21% | |
| Pattern: cytoplasmic only | 26 | 79% | |
| MHC I in tumor cells (n=40) | <25% TC | 25 | 63% |
| 25–75% TC | 8 | 20% | |
| >75% TC | 7 | 18% | |
| Clinico-pathologic characteristics | |||
| Tumor type (n=53) | De novo | 36 | 68% |
| Ex PA | 17 | 32% | |
| AJCC pT stage (n=52) | T1/T2 | 14 | 27% |
| T3/T4 | 38 | 73% | |
| AJCC pN stage (n=53) | Nx | 4 | 8% |
| N0 | 14 | 26% | |
| N+ | 35 | 66% | |
| Status at last follow up (n=46) | No evidence of disease | 20 | 43% |
| Alive with disease | 7 | 15% | |
| Dead of disease | 19 | 41% | |
| Recurrence (n=46) | No | 20 | 44% |
| Yes | 26 | 57% | |
| Distant metastasis | 16 | 35% | |
| Locoregional | 3 | 7% | |
| Both distant and locoregional | 7 | 15% | |